TGen-led international team identifies genes associated with suicide
Analysis of molecular-level biological changes could lead to better predictive models that would enhance assessment of suicide risk
PHOENIX, Ariz. — Jan. 10, 2022 — Is risk of suicide in our genes?
Findings of an international scientific team led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that gene expression studies could offer insights into the underlying causes of suicide, a highly complex public health problem that takes the lives of more than 800,000 people each year worldwide.
Examination of brain tissue samples from 380 individuals — 141 who died by suicide, and 239 who died of other causes — revealed five genes that affect several regions of the brain. The study results suggest that these genes may provide benefit toward helping prevent suicide. The findings appear in the journal European Neuropsychopharmacology.
“Should independent replications studies validate our findings, they might be able to inform predictive models of suicide risk in patients affected by mental disorders,” said Ignazio Piras, Ph.D., Research Assistant Professor in TGen’s Neurogenomics Division, and the study’s lead author.
“Our findings support the involvement in suicide behavior of astrocytes and microglia (brain and central nervous system cells), stress response, and the immune system,” Dr. Piras said.
Using the Gene Expression Omnibus, a genomic data repository run by the National Institutes of Health, researchers focused on three regions of the brain:
- Orbitofrontal cortex, which is involved in sensory detection, emotion and memory;
- Prefrontal cortex, which is associated with planning complex cognitive behavior, personality expression, decision making, and moderating social behavior;
- Dorsolateral prefrontal cortex, which is concerned with how to interact with stimuli.
A serious public health problem
Suicides contribute to 15% of all global deaths due to injury, a figure that is likely underestimated, according to previous studies. Risk prediction and the implementation of effective preventative models are among the top goals of suicide research. Previous models, based on clinical and behavioral assessments, have shown “extremely low” predictive validity.
In this study, researchers attempted to increase the predictive nature of risk models by integrating biological information from different studies conducted on a wide range of brain regions. Previous studies also showed statistically significant genomic associations among patients with mood disorders.
“Stratification of patients according to validated gene expression signatures will help risk assessment of suicidal behavior in the future,” said Mirko Manchia, M.D, Ph.D., Assistant Professor of Psychiatry at University of Cagliari (Italy), and one of the study’s senior authors.
The researchers found reduced expression of five key genes — KCNJ2, AGT, PMP2, VEZF1 and A2M — in the samples from individuals who died by suicide, all potentially linked to relevant alterations in molecular and cellular mechanisms. For example, previous studies have linked A2M to Alzheimer’s disease and neurocognitive decline.
These molecular targets have potential for follow-up analysis and implementation in risk prediction models.
“We will plan follow up studies, including additional data sources and integrative genomic analysis approaches, to validate the candidate targets,” said Clement Zai, Ph.D., Assistant Professor at the University of Toronto, and another of the study’s senior authors.
International team of collaborators
Also contributing to this study were: University of Ottawa (Canada), University of Barcelona (Spain), Dalhousie University (Canada), Centre for Addiction and Mental Health (Canada), and the Broad Institute (MIT/Harvard).
Support for the study — A review and meta-analysis of gene expression profiles in suicide — came from the University of Cagliari, the Spanish Ministry of Science and Innovation, the CAMH Foundation, the Brain and Behavior Research Foundation, and a Sylvia B. Chase Early Career Research Award.
# # #
About TGen, an affiliate of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: CityofHope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.
Media Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
